Roth Capital Starts Stock Coverage on ACADIA Pharmaceuticals (ACAD)

By admin | 6 years ago

Equities researchers at Roth Capital assumed coverage on shares of ACADIA Pharmaceuticals (NASDAQ: ACAD) in a report issued on Thursday. The firm set a “buy” rating on the stock.

Shares of ACADIA Pharmaceuticals traded up 1.46% during mid-day trading on Thursday, hitting $1.39. ACADIA Pharmaceuticals has a one year low of $0.90 and a one year high of $2.93. The company’s market cap is $73.6 million.

A number of other firms have also recently commented on ACAD. Analysts at Ladenburg Thalmann initiated coverage on shares of ACADIA Pharmaceuticals in a research note to investors on Monday, April 30th. They set a “buy” rating on the stock. Analysts at Needham & Company reiterated a “hold” rating on shares of ACADIA Pharmaceuticals in a research note to investors on Wednesday, March 7th.

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders.

About the author